Endometrial cancer (EC) is the most frequent malignant tumor of the female genital tract. Increasing evidence suggests that at least two different types of EC exist. Type I is associated with an endocrine milieu of estrogen predominance. These tumors are of endometrioid histology and develop from endometrial hyperplasia. They have a good prognosis and are sensitive to endocrine manipulation. Type II EC is not associated with a history of unopposed estrogens and develops from the atrophic endometrium of elderly women. They are of serous histology, have a poor prognosis, and do not react to endocrine manipulation. Both types of EC probably differ markedly with regard to the molecular mechanisms of malignant transformation. This article reviews reproductive and lifestyle factors modifying the risk of developing type I EC, including the use of hormonal contraceptives, hormone replacement therapy and tamoxifen. The roles of established and novel therapies for precancerous lesions and for invasive EC in the adjuvant and palliative settings are discussed.

This article has been cited by other articles:

				M. L. McCullough, A. V. Patel, R. Patel, C. Rodriguez, H. S. Feigelson, E. V. Bandera, T. Gansler, M. J. Thun, and E. E. Calle Body Mass and Endometrial Cancer Risk by Hormone Replacement Therapy and Cancer Subtype Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 73 - 79. [Abstract] [Full Text] [PDF]

				M. L. McCullough, E. V. Bandera, R. Patel, A. V. Patel, T. Gansler, L. H. Kushi, M. J. Thun, and E. E. Calle A Prospective Study of Fruits, Vegetables, and Risk of Endometrial Cancer Am. J. Epidemiol., October 15, 2007; 166(8): 902 - 911. [Abstract] [Full Text] [PDF]

				G. A Wood, J. E Fata, K. L M Watson, and R. Khokha Circulating hormones and estrous stage predict cellular and stromal remodeling in murine uterus Reproduction, May 1, 2007; 133(5): 1035 - 1044. [Abstract] [Full Text] [PDF]

				M. Sugimoto, S. Yoshida, S. Kennedy, M. Deguchi, N. Ohara, and T. Maruo Matrix Metalloproteinase-1 and -9 Promoter Polymorphisms and Endometrial Carcinoma Risk in a Japanese Population Reproductive Sciences, October 1, 2006; 13(7): 523 - 529. [Abstract] [PDF]

				A. G Gunin, I. N Kapitova, and N. V Suslonova Effects of histone deacetylase inhibitors on estradiol-induced proliferation and hyperplasia formation in the mouse uterus J. Endocrinol., June 1, 2005; 185(3): 539 - 549. [Abstract] [Full Text] [PDF]

				A. Lukanova and R. Kaaks Endogenous Hormones and Ovarian Cancer: Epidemiology and Current Hypotheses Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 98 - 107. [Abstract] [Full Text] [PDF]

				J. L. Bermejo, F. L. Buchner, and K. Hemminki Familial risk of endometrial cancer after exclusion of families that fulfilled Amsterdam, Japanese or Bethesda criteria for HNPCC Ann. Onc., April 1, 2004; 15(4): 598 - 604. [Abstract] [Full Text] [PDF]

				L. R. Zukerberg, R. L. DeBernardo, S. D. Kirley, M. D'Apuzzo, M. P. Lynch, R. D. Littell, L. R. Duska, L. Boring, and B. R. Rueda Loss of Cables, a Cyclin-Dependent Kinase Regulatory Protein, Is Associated with the Development of Endometrial Hyperplasia and Endometrial Cancer Cancer Res., January 1, 2004; 64(1): 202 - 208. [Abstract] [Full Text] [PDF]

				R. Kaaks, A. Lukanova, and M. S. Kurzer Obesity, Endogenous Hormones, and Endometrial Cancer Risk: A Synthetic Review Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1531 - 1543. [Abstract] [Full Text] [PDF]